The subsidiary of Guangdong Zhongsheng Pharmaceutical (002317.SZ), Zhongsheng Ruichuang Innovative Medicine RAY1225 Injection, has achieved the expected goals in Phase II clinical trials for weight reduction.

Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. ("Zhongsheng Ruichuang") has obtained top-line analysis data from a Phase II clinical trial of its independently developed innovative peptide drug RAY1225 injection for overweight/obese patients. Preliminary results show that RAY1225 injection demonstrated positive efficacy and good safety in Chinese adult overweight/obese participants, with the trial results meeting expectations. It is reported that RAY1225 injection is an innovative structural peptide drug developed by Zhongsheng Ruichuang with global independent intellectual property rights, belonging to the long-acting GLP-1 class of drugs with dual activation activity at GLP-1 receptor and GIP receptor. Phase II clinical studies of RAY1225 injection for both overweight/obese patients and type 2 diabetes patients are still ongoing. The Phase II clinical trial for overweight/obese patients (REBUILDING-1) recently completed data cleaning and locking for Part A sub-study, obtained top-line analysis results, met the primary endpoint, and significantly outperformed placebo in terms of weight loss rate and improvement of various cardiovascular and metabolic risk factors.